Aldosterone antagonists in congestive heart failure

Current Opinion in Investigational Drugs

Volumn 3, Issue 7, 2002, Pages 1024-1028

  Soberman, Judith ^a   Chafin, Carol C ^a   Weber, Karl T ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Aldosterone; Heart failure; Renin angiotensin; Spironolactone

Indexed keywords

ALDOSTERONE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN; CANRENONE; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; EPLERENONE; GLUCOCORTICOID RECEPTOR; LOOP DIURETIC AGENT; MINERALOCORTICOID RECEPTOR; POTASSIUM ION; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT;

ALDOSTERONE BLOOD LEVEL; ANTIHYPERTENSIVE ACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE COURSE; DIURETIC ACTIVITY; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; ENDOCRINE DISEASE; FIRST PASS EFFECT; GYNECOMASTIA; HUMAN; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; LIBIDO DISORDER; MENSTRUAL IRREGULARITY; PATHOPHYSIOLOGY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SIDE EFFECT;

ALDOSTERONE; ALDOSTERONE ANTAGONISTS; ANIMALS; CLINICAL TRIALS; HEART FAILURE, CONGESTIVE; HUMANS; RECEPTORS, ALDOSTERONE;

EID: 0036667099     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med (1999) 341:709-717. The RALES trial: A landmark study highlighting the salutary effect of aldosterone antagonists in congestive heart failure.
2. Gheorghiade M, Cody RJ, Francis GS, McKenna WJ, Young JB, Bonow RO: Current medical therapy for advanced heart failure. Am Heart J (1998) 132:S231-S248.
3. Davis JO: The physiology of congestive heart failure. In: Handbook of Physiology; Section 2: Circulation, vol III Hamilton WF (Ed), American Physiological Society, Washington, DC, USA (1965):2071-2122
4. O'Connor CM, Gattis WA, Swedberg K: Current and novel pharmacological approaches in advanced heart failure. Am Heart J (1998) 135:S249-S263.
5. MacFadyen RJ, Barr CS, Struthers AD: Aldosterone blockade reduces vascular collagen turnover, improves heart rate variability and reduces early morning rise in heart rate in heart failure patients. Cardiovasc Res (1997) 35:30-34. The first study to demonstrate the effect of spironolactone on both heart rate variability and markers of myocardial fibrosis in patients with congestive heart failure.
6. Zannad F: Angiotensin-converting enzyme inhibitor and spironolactone combination therapy. New objectives in congestive heart failure treatment. Am J Cardiol (1993) 71:34A-39A. A review article with comprehensive references discussing the effects of the interaction of spironolactone and ACE inhibitors on the pathophysiology of congestive heart failure.
7. Frishman WH: Recent advances in cardiovascular pharmacology. Curr Probl Cardiol (2000) 25:227-295.
8. Physicians' Desk Reference, 53rd Ed. Medical Economics Company, Montvale, NJ, USA (1999).
9. Waldorff S, Buch J: Canrenoate - A spironolactone metabolite. Acute cardiac effects in digitalized patients. Eur J Cardiol (1979) 10:143-149. A study of the effects of canrenoate on ventricular function.
10. Delyani J, Myles M, Funder J: Epleronone (SC 66110), a highly selective aldosterone antagonist. Am J Hypertens (1998) 11:94A.
11. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group. Circulation (1990) 82:1730-1736.
12. Eichhorn EJ, Tandon PK, DiBianco R, Timmis GC, Fenster PE, Shannon J, Packer M: Clinical and prognostic significance of serum magnesium concentration in patients with severe chronic congestive heart failure: The PROMISE Study. J Am Coll Cardiol (1993) 21:634-640.
13. Tsuji H, Venditti FJ Jr, Evans JC, Larson MG, Levy D: The association of levels of serum potassium and magnesium with ventricular premature complexes (the Framingham Heart Study). Am J Cardiol (1994) 74:232-235. A Framingham Heart Study analysis of the arrhythmic potential of decreased levels of potassium and magnesium.
14. Gottlieb SS, Baruch L, Kukin ML, Bernstein JL, Fisher ML, Packer M: Prognostic importance of the serum magnesium concentration in patients with congestive heart failure. J Am Coll Cardiol (1990) 16:827-831.
15. Struthers AD: Two new culprits in cardiovascular disease: QT dispersion and aldosterone. J Hum Hypertens (1995) 9:659-661.
16. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD: Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol (1995) 76:1259-1265.
17. Brilla CG, Weber KT: Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res (1992) 26:671-677. A study demonstrating the pathological effect of aldosterone excess on myocardial structure in an animal model.
18. Robert V, Van Thiem N, Cheav SL, Mouas C, Swynghedauw B, Delcayre C: Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension. Hypertension (1994) 24:30-36.
19. Barr CS, Naas A, Freeman N, Lang CC, Struthers AD: QT dispersion and sudden unexpected death in chronic heart failure. Lancet (1994) 343:327-329.
20. Wang W, McClain JM, Zucker IH: Aldosterone reduces baroreceptor discharge in the dog. Hypertension (1992) 19:270-277.
21. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S, Flaker GC, Klein M, Lamas GA, Packer M, Rouleau J, Rouleau JL, Rutherford J, Wertheimer JH, Hawkins CM: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med (1992) 327:669-677. The SAVE Trial, which demonstrated the beneficial effects of ACE inhibitioon following myocardial infarction in a large population.
22. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med (2000) 342:145-153. The HOPE Trial, which confirmed the benefit of ACE inhibition in patients at high risk for cardiovascular events.
23. Weber KT, Villarreal D: Role of aldosterone in congestive heart failure. Postgrad Med (1993) 93:203-207, 211-212, 216-218 passim.
24. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure (the Randomized Aldactone Evaluation Study [RALES]). Am J Cardiol (1996) 78:902-907.
25. Struthers AD: Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J (1995) 16:103-106.
26. Bashir Y, Sneddon JF, Staunton HA, Haywood GA, Simpson IA, McKenna WJ, Camm AJ: Effects of long-term oral magnesium chloride replacement in congestive heart failure secondary to coronary artery disease. Am J Cardiol (1993) 72:1156-1162.
27. And pressor agents in vascular smooth muscle. Hypertension (1983) 5:141-146.
28. Farquharson CAJ, Struthers AD: Spironlactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation (2000) 101:594-597.
29. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT: Remodeling of the rat right and left ventricle in experimental hypertension. Circ Res (1990) 67:1355-1364.
30. Brilla CG, Matsubara LS, Weber KT: Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol (1993) 25:563-575.
31. Sun Y, Ramires FJA, Weber KT: Fibrosis of atria and great vessels in response to angiotensin II or aldosterone infusion. Cardiovasc Res (1997) 35:138-147.
32. Campbell SE, Farb A, Weber KT: Pathologic remodelling of the myocardium in a weightlifter taking anabolic steroids. Blood Press (1993) 2:213-216.
33. Frierdich G, Schuh J, Brown M, Nochowiak D, Blehm D, Delyani JA: Effects of the selective mineralocorticoid receptor antagonist, eplerenone, in a model of aldosterone-induced hypertension and cardiac fibrosis. Am J Hypertens (1998) 11:94A.
34. Delyani JA: Mineralocorticoid receptor antagonists: The evolution of utility and pharmacology. Kidney Int (2000) 57:1408-1411. A pharmacological review of the actions of aldosterone receptor antagonists.
35. Klappacher G, Franzen P, Haab D, Mehrabi M, Binder M, Plesch K, Pacher R, Grimm M, Pribill I, Eichler H-G, Glogar HD et al: Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol (1995) 75:913-918.
36. Høst NB, Jensen LT, Bendixen PM, Jensen SE, Koldkjær OG, Simonsen EE: The aminoterminal propeptide of type III procollagen provides new information on prognosis after acute myocardial infarction. Am J Cardiol (1995) 76:869-873.
37. Zannad F, Alla F, Dousset B, Perez A, Pitt B: Limitatioon of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: Insights from the randomized aldactone evaluation study (RALES). RALES Investigators. Circulation (2000) 102:2700-2706. An analysis of the RALES Trial population investigating the effects of spironolactone on markers of myocardial fibrosis.
38. Pitt B: ACE inhibitor co-therapy in patients with heart failure: Rationale for the Randomized Aldactone Evaluation Study (RALES). Eur Heart J (1995) 16:107-110.
39. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N Engl J Med (1987) 316:1429-1435. The CONSENSUS trial; one of the earlier trials to document the reduction in morbidity and mortality associated with ACE inhibitor therapy for congestive heart failure.